Literature DB >> 8498312

Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.

B P Kimball1, S Bui, E D Wigle.   

Abstract

To evaluate the acute hemodynamic effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy (HOCM), 25 patients (12 men, 13 women) with an average age of 40 years (range 18 to 70 years) were evaluated while undergoing cardiac catheterization-angiography. Biplane left ventricular angiography was performed with standard intracardiac-systemic hemodynamics, including resting and provoked (after ventricular premature beat) left ventricular outflow tract gradients, by using simultaneous LV and aortic pressures as disopyramide was being administered (total dose 100 mg, bolus 10 mg every 3 minutes). Average baseline thermodilution cardiac output equalled 4.5 +/- 1.2 L/min, with all 25 subjects demonstrating systolic anterior motion of the mitral apparatus (mild, 3 [12%]; moderate, 8 [32%]; severe, 14 [64%]). Although heart rate originally slowed during disopyramide administration, average heart rate increased during the final stages (before, 78 +/- 15 vs after, 82 +/- 13 beats/min; p < 0.05). Systemic aortic pressures increased during intravenous disopyramide (before, 107 +/- 21/71 +/- 19 mm Hg vs after, 120 +/- 28/81 +/- 13 mm Hg; p < 0.05), with a decline in LV end-diastolic pressure (before, 19 +/- 7 vs after, 16 +/- 6 mm Hg; p < 0.01). Maximum LV systolic pressures decreased (before, 193 +/- 32 vs after, 146 +/- 29 mm Hg; p < 0.01), with a substantial reduction in resting LV outflow tract gradients (before, 86 +/- 34 vs after, 27 +/- 20 mm Hg; p < 0.001) in conjunction with less inducible obstruction (before, 124 +/- 33 vs after, 64 +/- 33 mm Hg; p < 0.001). Only minor electrocardiographic changes were seen during disopyramide infusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498312     DOI: 10.1016/0002-8703(93)90760-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.

Authors:  K Niki; M Sugawara; S Tanino; K Iwade; S Hosoda; H Kasanuki
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Disopyramide improves the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy.

Authors:  K Niki; M Sugawara; R Asano; T Oka; Y Kondoh; S Tanino; K Iwade; N Magosaki; H Kasanuki; S Hosoda
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

3.  Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.

Authors:  Shintaro Haruki; Yuichiro Minami; Atsushi Suzuki; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2014-06-12       Impact factor: 2.037

4.  Medical therapy versus interventional therapy in hypertropic obstructive cardiomyopathy.

Authors:  Hubert Seggewiss
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

Review 5.  [Clinical picture and therapy of hypertrophic cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss
Journal:  Med Klin (Munich)       Date:  1998-04-15

6.  Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Josè Manuel Pioner; Lorenzo Santini; Zhinuo J Wang; Chiara Palandri; Marina Scardigli; Giulia Vitale; Leonardo Sacconi; Pierluigi Stefàno; Laura Flink; Katherine Riedy; Francesco Saverio Pavone; Elisabetta Cerbai; Corrado Poggesi; Alessandro Mugelli; Alfonso Bueno-Orovio; Iacopo Olivotto; Mark V Sherrid
Journal:  JACC Basic Transl Sci       Date:  2019-10-09

Review 7.  Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.

Authors:  Mark V Sherrid
Journal:  Curr Cardiol Rev       Date:  2016
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.